Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Tenon Medical (NASDAQ:TNON): Can Catamaran's Growth Outpace Its Losses?

● The company's losses deepened as it invested in commercialization.

Vinay Lochav | 27 August 2026

Vivos Therapeutics (NASDAQ:VVOS) Wins a New Patent: Could It Open a Bigger Sleep-Apnea Market?

●New patent:On August 5, 2026, Vivos announced U.S.PatentNo. 12,697,190, broadening protection for its Vivos CARE oral medical-device technology.

Vinay Lochav | 27 August 2026

GeoVax Labs (NASDAQ:GOVX): Does Its Vaccine Pipeline Offer a Way Forward?

GeoVax Labs (NASDAQ:GOVX) is advancing an ambitious vaccine and immunotherapy pipeline against a backdrop of tight finances. The company is pushing forward with late-stage plans for a smallpox and mpox vaccine while flagging the funding challenges that shadow many small biotechs.

Vinay Lochav | 27 August 2026

Kairos Pharma's (NYSE:KAPA) Bayer Deal and Prostate Cancer Data: Does It Deserve a Fresh Look?

Kairos Pharma (NYSE:KAPA) is a small oncology company assembling a body of clinical evidence for a novel antibody, and a series of positive interim readouts has begun to build a case that the stock deserves a fresh look. The company's lead candidate targets a …

Vinay Lochav | 27 August 2026

MDxHealth (NASDAQ:MDXH): Can Double-Digit Growth in Urologic Diagnostics Continue?

● The company described a rebound in revenue and maintained its guidance.

Vinay Lochav | 27 August 2026

Nano-X Imaging (NASDAQ:NNOX): Why This Medical-Imaging Stock Deserves a Second Look

Nano-X Imaging (NASDAQ:NNOX) is pursuing an ambitious vision to make medical imaging more accessible through novel X-ray technology and AI, and recent commercial deals suggest the company is quietly building momentum. After years of development and skepticism, Nano-X has been signing multi-year deployment agreements …

Vinay Lochav | 27 August 2026

OSR Health (OTC:OSRH) Heats Up: Is It Becoming the Market's Next Breakout Story?

●Delisting determination:On August 19, 2026, OSR Health disclosed it had received aNasdaqStaff Delisting Determination for failing to maintain the $1.00 minimum bid price.

Vinay Lochav | 27 August 2026

Quince Therapeutics (NASDAQ:QNCX): After a Failed Pivotal Trial, What's Next?

Quince Therapeutics (NASDAQ:QNCX) has had one of the more difficult years a clinical-stage biotech can face: its pivotal trial failed, and the company moved to halt development of its lead program. Investors considering the shares should focus on what the company actually has left …

Vinay Lochav | 27 August 2026

Aldeyra Therapeutics (NASDAQ:ALDX) Wins FDA Acceptance: Is Reproxalap Back on Track?

Aldeyra Therapeutics (NASDAQ:ALDX) has spent years navigating a winding regulatory path for its dry-eye-disease drug, and the story has reached another pivotal juncture. After earlier setbacks with the FDA, the company resubmitted its application for reproxalap, secured FDA acceptance for review, and expanded aPartnershipwith …

Vinay Lochav | 27 August 2026

Curis (NASDAQ:CRIS) Cools After a Volatile Run: Could Emavusertib Spark a Rebound?

●Strong response data:Curis reported an 86% response rate in a BTK-inhibitor-naive lymphoma setting for emavusertib, its lead IRAK4 inhibitor.

Vinay Lochav | 27 August 2026
Support

Hi! How can we help you today?

Loading…